These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8960716)

  • 1. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.
    Thal LJ; Schwartz G; Sano M; Weiner M; Knopman D; Harrell L; Bodenheimer S; Rossor M; Philpot M; Schor J; Goldberg A
    Neurology; 1996 Dec; 47(6):1389-95. PubMed ID: 8960716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.
    van Dyck CH; Newhouse P; Falk WE; Mattes JA
    Arch Gen Psychiatry; 2000 Feb; 57(2):157-64. PubMed ID: 10665618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease.
    Thal LJ; Ferguson JM; Mintzer J; Raskin A; Targum SD
    Neurology; 1999 Apr; 52(6):1146-52. PubMed ID: 10214735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physostigmine for Alzheimer's disease.
    Coelho F; Birks J
    Cochrane Database Syst Rev; 2001; 2001(2):CD001499. PubMed ID: 11405996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease.
    Imbimbo BP; Martelli P; Troetel WM; Lucchelli F; Lucca U; Thal LJ
    Neurology; 1999 Mar; 52(4):700-8. PubMed ID: 10078713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease.
    Imbimbo BP; Troetel WM; Martelli P; Lucchelli F
    Dement Geriatr Cogn Disord; 2000; 11(1):17-24. PubMed ID: 10629357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
    Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
    Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease.
    Imbimbo BP; Lucca U; Lucchelli F; Alberoni M; Thal LJ
    Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):313-22. PubMed ID: 9876959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
    Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
    J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group.
    Le Bars PL; Katz MM; Berman N; Itil TM; Freedman AM; Schatzberg AF
    JAMA; 1997 Oct 22-29; 278(16):1327-32. PubMed ID: 9343463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
    Zemlan FP
    J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
    Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
    Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.
    Feldman HH; Doody RS; Kivipelto M; Sparks DL; Waters DD; Jones RW; Schwam E; Schindler R; Hey-Hadavi J; DeMicco DA; Breazna A;
    Neurology; 2010 Mar; 74(12):956-64. PubMed ID: 20200346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
    Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
    N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group.
    Imbimbo BP; Verdelli G; Martelli P; Marchesini D
    Dement Geriatr Cogn Disord; 1999; 10(2):139-47. PubMed ID: 10026388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
    Farlow M; Gracon SI; Hershey LA; Lewis KW; Sadowsky CH; Dolan-Ureno J
    JAMA; 1992 Nov; 268(18):2523-9. PubMed ID: 1404819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type.
    Möller H-J ; Hampel H; Hegerl U; Schmitt W; Walter K
    Pharmacopsychiatry; 1999 May; 32(3):99-106. PubMed ID: 10463377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
    Rogers SL; Farlow MR; Doody RS; Mohs R; Friedhoff LT
    Neurology; 1998 Jan; 50(1):136-45. PubMed ID: 9443470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.